Health Care & Life Sciences » Biotechnology | RXi Pharmaceuticals Corp.

RXi Pharmaceuticals Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
399.00
71.00
34.00
19.00
15.00
SG&A Expense
21,249.00
8,810.00
10,194.00
8,981.00
9,311.00
EBIT
20,949.00
8,826.00
10,237.00
9,015.00
9,366.00
Unusual Expense
-
-
-
-
4,705.00
Non Operating Income/Expense
-
9.00
2.00
6.00
2.00
Pretax Income
20,925.00
8,800.00
10,223.00
8,994.00
14,073.00
Income Tax
-
-
-
-
1,621.00
Consolidated Net Income
20,925.00
8,800.00
10,223.00
8,994.00
12,452.00
Net Income
20,925.00
8,800.00
10,223.00
8,994.00
12,452.00
Net Income After Extraordinaries
20,925.00
8,800.00
10,223.00
8,994.00
12,452.00
Net Income Available to Common
29,535.00
12,930.00
10,432.00
11,069.00
12,452.00
EPS (Basic)
288.00
79.00
21.00
16.40
5.52
Basic Shares Outstanding
102.60
163.60
497.00
674.60
2,257.80
EPS (Diluted)
287.75
79.02
20.99
16.41
5.52
Diluted Shares Outstanding
102.60
163.60
497.00
674.60
2,257.80
EBITDA
20,850.00
8,739.00
10,160.00
8,962.00
9,296.00
Non-Operating Interest Income
24.00
17.00
16.00
15.00
-
Preferred Dividends
8,610.00
4,130.00
209.00
2,075.00
-

About RXi Pharmaceuticals

View Profile
Address
257 Simarano Drive
Marlborough Massachusetts 01752
United States
Employees -
Website http://www.rxipharma.com
Updated 09/14/2018
RXi Pharmaceuticals Corp. is a biotechnology company, which engages in developing therapeutics that address unmet medical needs. Its clinical product candidate includes RXI-109, a RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.